Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.